Compare AVPT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVPT | VCEL |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | AVPT | VCEL |
|---|---|---|
| Price | $11.52 | $46.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $16.64 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.5M | 720.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $25.00 | $19.40 |
| Revenue Next Year | $19.63 | $18.24 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $8.84 | $28.95 |
| 52 Week High | $19.95 | $47.06 |
| Indicator | AVPT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 76.08 |
| Support Level | $11.49 | $32.47 |
| Resistance Level | $14.33 | N/A |
| Average True Range (ATR) | 0.46 | 1.66 |
| MACD | 0.09 | 0.58 |
| Stochastic Oscillator | 88.73 | 97.36 |
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.